Novo Nordisk investing in China's biopharma supply chain

Novo Nordisk is investing in the Chinese biopharmaceuticals supply chain with the establishment of a new research and development centre.

Novo Nordisk is investing in the Chinese biopharmaceuticals supply chain with the establishment of a new research and development centre.

The company, which opened its first research centre in the country in 1997, said that this latest move is a reaffirmation of its long-term commitment to China.

The $100 million state-of-the-art science facility will expand its capabilities for conducting protein research in China.
"We see the investment in this new R&D facility as a win-win opportunity for both Novo Nordisk and China," said Mads Krogsgaard Thomsen, chief science officer and executive vice president for the company.

"Novo Nordisk recognises the strong science being performed in China and we want to bring innovation from Chinese scientists into our company to help tackle the growing burden of diabetes and other chronic diseases throughout the world.

The centre is situated at an existing site that has already contributed significantly to its research and development portfolio for diabetes and biopharmaceutical target disease areas.